Scopus BioPharma launches new unit, shares soar

Scopus Biopharma

02/09/2021 15:17

** Shares of drug developer  SCPS.O  jump 33.5% to a near
2-month high of $6.69
    ** Co says it has launched a wholly owned unit, Duet
Therapeutics, integrating the clinical development of the
immunotherapy candidates of Scopus and Olimmune  urn:newsml:reuters.com:*:nGNX2npQKj
    ** Los Angeles-based drug developer Olimmune was acquired by
SCPS in June this year
    ** Co says DUET-01, a monotherapy candidate is in an
early-stage trial in B-cell non-Hodgkin lymphoma, a cancer which
starts in the body's immune system
    ** Duet expects to file applications in 2022 to start human
clinical trials of another candidate for genital and urinary,
and head and neck cancers - co
    ** Stock down 55% YTD, including session's moves

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))